Financial Ratios

PANACEA BIOTEC LTD.

NSE : PANACEABIOBSE : 531349ISIN CODE : INE922B01023Industry : Pharmaceuticals & DrugsHouse : Soshil Kumar Jain
BSE121.30-2.15 (-1.74 %)
PREV CLOSE ( ) 123.45
OPEN PRICE ( ) 124.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16279
TODAY'S LOW / HIGH ( )120.35 127.40
52 WK LOW / HIGH ( )107.15 202.2
NSE121.55-1.95 (-1.58 %)
PREV CLOSE( ) 123.50
OPEN PRICE ( ) 123.90
BID PRICE (QTY) 121.55 (5489)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 300190
TODAY'S LOW / HIGH( ) 120.30 127.60
52 WK LOW / HIGH ( )107 202.5
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-14.29-15.28-2.35-24.994.34
   CEPS(Rs)-10.29-10.961.98-20.5413.11
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)53.1767.7782.97140.5368.32
   Tax Rate(%)-39.510.00-12.15-12.5828.53
Margin Ratios
   Core EBITDA Margin(%)-24.21-30.750.141.96-33.01
   EBIT Margin(%)-20.36-36.62-1.532.2031.93
   Pre Tax Margin(%)-24.25-39.60-3.69-26.578.37
   PAT Margin (%)-33.84-39.60-4.14-29.925.98
   Cash Profit Margin (%)-24.37-28.413.49-24.5818.07
Performance Ratios
   ROA(%)-9.57-9.88-1.27-10.561.56
   ROE(%)-23.64-20.27-2.11-23.936.59
   ROCE(%)-11.36-16.14-0.701.0911.51
   Asset Turnover(x)0.280.250.310.350.26
   Sales/Fixed Asset(x)0.300.280.410.520.34
   Working Capital/Sales(x)-5.0050.585.991.14-89.21
Efficiency Ratios
   Fixed Capital/Sales(x)3.323.582.431.912.96
   Receivable days25.1145.2627.7715.2968.81
   Inventory Days173.06167.0397.6450.5578.73
   Payable days306.74437.99269.16258.86324.70
Valuation Parameters
   PER(x)0.000.000.000.0045.69
   PCE(x)-10.53-13.5289.37-5.3315.12
   Price/Book(x)2.042.192.140.782.90
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)2.814.033.091.384.27
   EV/Core EBITDA(x)-25.64-15.8050.0412.55-13.68
   EV/EBIT(x)-13.72-10.97-199.1960.0713.36
   EV/CE(x)0.811.021.100.521.19
   M Cap / Sales2.583.863.161.372.73
Growth Ratio
   Net Sales Growth(%)9.16-31.45-29.8410.25-22.64
   Core EBITDA Growth(%)53.09-383.02-60.64138.96-239.83
   EBIT Growth(%)39.11-1521.99-147.32-92.05237.69
   PAT Growth(%)6.45-549.2590.58-676.10136.97
   EPS Growth(%)6.45-549.2590.58-676.09136.97
Financial Stability Ratios
   Total Debt/Equity(x)0.310.200.130.081.65
   Current Ratio(x)0.791.021.293.670.99
   Quick Ratio(x)0.330.490.853.080.95
   Interest Cover(x)-5.24-12.29-0.710.081.36
   Total Debt/Mcap(x)0.150.090.060.100.57

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.